【摘要】 目的：探讨检测AML1－ETO融合转录本在t（8；21）急性髓细胞白血病M2型M2／t（8；21）的临床诊断和预后判断中的意义。方法：用G显带技术对初治M2患者作染色体核型分析，用半筑巢式逆转录聚合酶链反应（RT／PCR）技术检测AML1－ETO融合基因转录本。结果：14例初治M2中共检出9例存在AMLI-ETO融合基因转录本，阳性率为64．3％。细胞遗传学技术证实9例均有t（8；21）易位；5例为阴性，均无t（8；21）易位；4例伴t（8;21）易位患者在处于完全缓解后5～72月，RT／PCR结果仍持续阳性。结论：应用筑巢式RT／PCR技术近似半定量检测AMLI－ETO融合转录本，对M2／t（8；21）的诊断和预后判断具有重要临床价值。更多还原

【Abstract】 Objective To study the clinical significance of detection of AML1-ETO fusion gene in diagnosis and prognosis for t(8; 21) acute myelogenous leukemia M2 (M2/t(8; 21). Methods Karyo type was analyzed in patients with AML-M2 diagnosed by a tyrpsin-Giemsa banding technique. AML1-ETO fusion transcripts were detected by reverse-transcriptase polymerase Chain reaction (RT/PCR). Results Of the 14 patients with M2 diagnosed by RT/PCR approach, the AML1-ETO fusion transcript was amplified in 9 with the positive rate of 64. 3 %. The t(8; 21) translocation was detected in the 9 cases by cytogenetic analysis. The other 5 cases were not found AML1-ETO fusion transeript and t(8; 21) translocation. 4 patients with t(8;21) showed minimal residual disease 5-72 months after complete remission. Conclusion The nested RT／PCR could be used to detect teh AML1-ETO fusion transcript semi-quantitatively, and appeared to be of value diagnosis and predicting the prognosis of M2/t(8; 21).更多还原